EMA · European Union
vandetanib — EMA regulatory status
vandetanib (ZACTIMA) regulatory status in the European Union is tracked from public EMA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: EMA approved.
Status snapshot
- Status
- EMA approved
- Brand
- ZACTIMA
- Mechanism
- Ephrin receptor inhibitor
- Target
- Ephrin receptor
- Structured fields
- 6
Pharmacology context used for competitive intelligence: Ephrin receptor inhibitor. Target: Ephrin receptor. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — EMA: approved.
Linked evidence on this spoke: 5 published clinical programs and 0 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| EMA | European Union | approved | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| J2G-MC-JZJB | Phase 3 | Eli Lilly and | 2023-506782-56-00 |
| Vandetanib | Phase 3 | Sanofi Pasteur MSD | NCT01298323 |
| Vandetanib | Phase 3 | Sanofi Pasteur MSD | NCT00364351 |
| ZD6474 (vandetanib) | Phase 3 | Sanofi Pasteur MSD | NCT00404924 |
| ZD6474 | Phase 2 | United Therapeutics Europe | NCT00402896, NCT00410189 |
Related hubs
FAQ
What is the EMA approval status of vandetanib?
vandetanib currently shows EMA approved in our European Union regulatory index. Confirm on the official EMA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get vandetanib regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to vandetanib?
This spoke lists 5 published programs associated with vandetanib in our pipeline index.